In Vitro Diagnostic Industry’s Political Playbook Rewritten As Firms Lobby On COVID-19 Legislation

Diagnostic companies spent tens of thousands of dollars to influence outcome of coronavirus bills in February, March

Test kit and lab firms spent tens of thousands of dollars in the first quarter of 2020 lobbying legislators to win provisions in coronavirus protection laws to ensure COVID-19 diagnostics would be a top US legislative priority.

The inscription on a red background coronavirus on the background of the building of the US Congress building of the capitol building on a clear day. Close-up. Epidemic concept in washington and usa

More from Policy & Regulation

More from Medtech Insight